Management of Splenomegaly

Diagnostic Assessment

Splenomegaly is defined as spleen length greater than 13 cm when measured in the coronal plane on imaging studies, with proper measurement technique being crucial, including vertical length measurement in the coronal image or calculation by multiplying the number of spleen slices in transverse CT views by slice thickness, according to the Annals of Oncology 1
Initial evaluation should include complete blood count, reticulocyte count, and abdominal imaging (CT or ultrasound) to confirm splenomegaly and evaluate for associated findings, as recommended by the Journal of Clinical Oncology 2
Assessment for signs of systemic illness that commonly cause splenomegaly, including hematologic malignancies (lymphoma, leukemia), is necessary, as stated in Blood 3
Liver disease is another potential cause of splenomegaly, as noted in the Journal of Clinical Oncology 2
Infections can also lead to splenomegaly, according to Pediatrics 4

Clinical Significance

Splenomegaly of 14 cm is clinically significant as it exceeds the normal threshold (13 cm) established in the Lugano Classification and RECIL 2017 criteria, as stated in the Annals of Oncology and the Journal of Clinical Oncology 1, 2
A spleen of this size may cause abdominal discomfort or pain, early satiety, and potential hematologic abnormalities due to sequestration, as reported in Pediatrics 4

Management Approach

Treatment of Underlying Cause

Lymphoma requires chemotherapy regimens appropriate for the specific lymphoma subtype, as stated in Blood 3
Myeloproliferative disorders may be treated with cytoreductive therapy, JAK inhibitors, or consideration for allogeneic stem cell transplantation, according to Blood 5
Infections should be treated with appropriate antimicrobial therapy, as noted in Pediatrics 4

Monitoring

Regular monitoring of spleen size is recommended during treatment of the underlying condition, as stated in the Annals of Oncology 1
For patients with lymphoma, response assessment should include measurement of spleen size, with regression of splenomegaly being part of treatment response criteria, as reported in the Journal of Clinical Oncology 2, 6
In the setting of lymphoma, spleen must regress by at least 50% in length beyond normal to be considered a partial response, according to the Journal of Clinical Oncology 6

Specific Interventions for Splenomegaly

For patients with myeloproliferative disorders and symptomatic splenomegaly, hydroxyurea-based cytoreduction may be considered, as stated in Blood 5
For patients with splenic sequestration, careful monitoring for acute changes in blood counts and red blood cell transfusions may be necessary, as noted in Pediatrics 4

Surgical Considerations

Splenectomy is generally not indicated for splenomegaly of 14 cm unless there are complications such as refractory symptoms despite medical management, as stated in the Journal of the American College of Radiology 7
For splenic abscesses, percutaneous drainage is preferred over splenectomy when technically feasible to preserve splenic function, according to the Journal of the American College of Radiology 7

Precautions and Complications

Patients with splenomegaly are at risk of cytopenias due to splenic sequestration, splenic infarction, and infection risk if splenic function is compromised, as reported in Pediatrics 4
For patients with myeloproliferative disorders and iron overload, consider iron chelation therapy if ferritin exceeds 1000 μg/L, as stated in Blood 5

Follow-up

Regular follow-up imaging to assess changes in spleen size in response to treatment is recommended, as stated in the Annals of Oncology 1
For lymphoma patients, imaging intervals of 2-3 months during the first year of therapy are recommended, with less frequent imaging thereafter, according to the Annals of Oncology 1

Evaluation and Management of Splenomegaly

Diagnostic Approach and Common Etiologies

Myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia, are common etiologies of splenomegaly 8, 9

Management of Myeloproliferative Disorder-Associated Splenomegaly

The American Society of Hematology recommends JAK inhibitors, such as ruxolitinib, as first-line therapy for symptomatic splenomegaly in myeloproliferative disorders, with a significant reduction in spleen volume and improvement in symptoms 10
Hydroxyurea is an alternative option for controlling symptomatic splenomegaly, with an approximate 40% response rate 9
Splenectomy may be considered for patients with massively enlarged spleen (>20 cm below costal margin) or those who are refractory to medical therapy, with a perioperative mortality of 5-10% and morbidity up to 25% 11, 12

Management of Associated Complications

For anemia, erythropoiesis-stimulating agents, androgens, or danazol may be used, with response rates ranging from 23-60% 8, 9
JAK inhibitors are effective in controlling constitutional symptoms associated with splenomegaly 10
Low-dose radiation therapy is the treatment of choice for non-hepatosplenic extramedullary hematopoiesis 12

Outpatient Treatment of Splenomegaly

Disease-Specific Outpatient Treatment Approaches

Hydroxyurea is the first-line outpatient treatment for symptomatic splenomegaly, achieving spleen volume reduction in approximately 40% of patients, as recommended by the American Society of Clinical Oncology 13, 14
Intravenous cladribine (5 mg/m²/day for 5 consecutive days, repeated for 4-6 monthly cycles) is an alternative option for hydroxyurea-refractory disease, as suggested by the American Society of Clinical Oncology 13, 14
Oral melphalan (2.5 mg three times weekly) or oral busulfan (2-6 mg/day with close blood count monitoring) can be used as alternative options for hydroxyurea-refractory disease, as recommended by the American Society of Clinical Oncology 13, 14
Interferon therapy is poorly tolerated and has limited efficacy in primary myelofibrosis, according to the American Society of Clinical Oncology 13, 14

Special Considerations

For patients with sickle cell disease and splenic sequestration, urgent evaluation and potential red blood cell transfusion are required, as recommended by the American Academy of Pediatrics 15
Parents of patients with sickle cell disease should be taught to check spleen size daily and seek urgent care for enlargement, as advised by the American Academy of Pediatrics 15
Splenectomy may be indicated after recovery from life-threatening or recurrent episodes of splenic sequestration in patients with sickle cell disease, as suggested by the American Academy of Pediatrics 15

When Outpatient Management Is Insufficient

Referral for inpatient or surgical evaluation is necessary for patients with drug-refractory symptomatic splenomegaly causing severe cachexia or pain, as recommended by the American Society of Clinical Oncology 13, 14
Referral for inpatient or surgical evaluation is also necessary for patients with symptomatic portal hypertension with variceal bleeding or ascites, as recommended by the American Society of Clinical Oncology 13, 14
Established transfusion-dependent anemia is another indication for referral for inpatient or surgical evaluation, as recommended by the American Society of Clinical Oncology 13, 14
Splenectomy in myeloproliferative disorders carries significant risks, including 5-10% perioperative mortality and up to 50% complication rate, as reported by the American Society of Clinical Oncology 13, 14

Diagnostic and Monitoring Guidelines for Splenomegaly

Physical Examination Accuracy

Physical examination detects hepatomegaly with approximately 60 % sensitivity and 44 % specificity, while splenomegaly detection shows about 93 % sensitivity but only 57 % specificity for identifying advanced disease. 16

Essential Laboratory Evaluation

At clinical stability, guidelines advise obtaining a complete blood count with differential, peripheral blood smear review by a qualified hematologist, reticulocyte count, liver function tests (AST, ALT, alkaline phosphatase, GGT, bilirubin), and platelet count. 16

Response Assessment for Myeloproliferative Neoplasms

Spleen response is defined as either (a) baseline palpable splenomegaly 5–10 cm below the left costal margin becoming non‑palpable, or (b) baseline palpable splenomegaly >10 cm decreasing by ≥50 %; radiologic confirmation requires MRI or CT showing ≥35 % reduction in spleen volume. 17

Cystic Fibrosis–Specific Recommendations

Annual abdominal physical examination for hepatosplenomegaly should begin at the time of cystic fibrosis diagnosis. 16
Abdominal ultrasound is recommended at least every two years from early childhood (age 3) through late adolescence. 16
In cystic fibrosis patients, the presence of splenomegaly signals advanced liver disease with portal hypertension. 16

Evidence‑Based Recommendations for Splenomegaly in Elderly Patients

Myeloproliferative Neoplasms

Molecular testing for JAK2, CALR, and MPL mutations is recommended to confirm a myeloproliferative neoplasm in older adults presenting with splenomegaly. 18
Elderly patients with a myeloproliferative disorder and thrombocytosis have a heightened risk of thrombosis, indicating the need for vigilant thrombotic risk assessment and prophylaxis. 18
Management plans should incorporate serial complete blood‑count (CBC) monitoring, with the frequency of testing individualized according to the specific underlying hematologic diagnosis. 18

Infectious Etiologies

Infective endocarditis should be included in the differential diagnosis of splenomegaly in the elderly, as roughly 30 % of endocarditis cases exhibit splenomegaly. 19
When a splenic abscess is suspected (e.g., persistent fever or bacteremia), a contrast‑enhanced CT or MRI is advised, providing 90–95 % sensitivity for detection. 19
Splenic infarction can progress to an abscess; therefore, patients with suspected infarction should undergo CT or MRI to evaluate for this complication. 19